Iterum Therapeutics PLC
NASDAQ:ITRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Iterum Therapeutics PLC
Other Current Liabilities
Iterum Therapeutics PLC
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Other Current Liabilities
$356k
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Other Current Liabilities
$47.6m
|
CAGR 3-Years
50%
|
CAGR 5-Years
40%
|
CAGR 10-Years
-3%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Other Current Liabilities
$60.6m
|
CAGR 3-Years
96%
|
CAGR 5-Years
14%
|
CAGR 10-Years
35%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Other Current Liabilities
$5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Other Current Liabilities
$4.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Other Current Liabilities
€10m
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
See Also
What is Iterum Therapeutics PLC's Other Current Liabilities?
Other Current Liabilities
356k
USD
Based on the financial report for Sep 30, 2025, Iterum Therapeutics PLC's Other Current Liabilities amounts to 356k USD.
What is Iterum Therapeutics PLC's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-59%
Over the last year, the Other Current Liabilities growth was -11%. The average annual Other Current Liabilities growth rates for Iterum Therapeutics PLC have been -46% over the past three years , -59% over the past five years .
